“ The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and fill an unmet medical need based on a surrogate endpoint”
The Efti/Keytruda combo ,approximately 8x the Keytruda mono results in head and neck cancer.With 5 complete responses in a extremely difficult to treat indication,with limited options.
Tumour shrinkage is considered to be a surrogate end point.
Overnight Market report, page-1488
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $480.0M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.5¢ | 32.0¢ | $1.703M | 5.215M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 211685 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 279000 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |